jRCT2080224836终止3 期
A comparison study on WP-1303 and ripasudil ophthalmic solution in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 280
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, Randomized, Single-masked, Parallel-group
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients with POAG or OH.
- •IOP is less than 35mmHg for both eyes.
- •One eye is greater than or equal to 21mmHg.
排除标准
- •Patients who have visual acuity of less than 0.
- •Presence of active eye disease (eg., uveitis, ocular infection, severe dry eye).
- •Pregnant women, lactating women or women who desire to be pregnant.
- •Patients who is judged inappropriate to participate in the study by investigator or sub-investigator.
结局指标
主要结局
-
safety efficacy efficacy:intraocular pressure safety:adverse event and adverse drug reaction
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
未知
3 期
Comparison of efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidismSecondary hyperparathyroidismJPRN-jRCT2080221462Abbott Japan Co., Ltd.252
进行中（未招募）
1 期
A Phase III Study to Compare the Effect of Panzyga and Placebo in Patients with PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome)Pediatric acute-onset neuropsychiatric syndrome (PANS)MedDRA version: 25.0Level: LLTClassification code 10086608Term: PANSSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2020-000867-21-SEOctapharma Pharmazeutika Produktionsges.m.b.H.92
进行中（未招募）
1 期
A superiority study to compare the effect of Panzyga versus placebo in patients with pediatric acute-onset neuropsychiatric syndromePediatric acute-onset neuropsychiatric syndrome (PANS)MedDRA version: 25.0Level: LLTClassification code: 10086608Term: PANS Class: 100000004848CTIS2024-511673-30-00Octapharma Pharmazeutika Produktionsgesellschaft mbH92
已完成
3 期
A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumabJPRN-UMIN000027938Japan Breast Cancer Research Group446
进行中（未招募）
3 期
JBCRG-M06(EMERALD)HER2-positive progressive-recurrent breast cancerJPRN-jRCTs021180027Yamashita Toshinari480